HC Wainwright Brokers Reduce Earnings Estimates for Vericel

Vericel Co. (NASDAQ:VCEL - Free Report) - Analysts at HC Wainwright dropped their Q4 2024 earnings per share estimates for Vericel in a report released on Friday, November 8th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.37 for the quarter, down from their prior estimate of $0.38. HC Wainwright currently has a "Buy" rating and a $60.00 target price on the stock. The consensus estimate for Vericel's current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Vericel's Q3 2025 earnings at $0.09 EPS.

Other equities analysts have also issued research reports about the stock. Stephens increased their target price on shares of Vericel from $56.00 to $58.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. TD Cowen boosted their target price on shares of Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, August 27th. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a research report on Friday. Canaccord Genuity Group assumed coverage on shares of Vericel in a report on Friday, August 9th. They issued a "buy" rating and a $57.00 target price on the stock. Finally, Truist Financial boosted their target price on shares of Vericel from $56.00 to $57.00 and gave the stock a "buy" rating in a report on Tuesday, July 16th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and an average price target of $57.71.

Vericel Price Performance

Shares of NASDAQ:VCEL traded up $2.78 on Monday, hitting $56.78. The company's stock had a trading volume of 596,222 shares, compared to its average volume of 430,598. The company has a 50-day simple moving average of $44.27 and a 200 day simple moving average of $46.41. Vericel has a 1 year low of $32.31 and a 1 year high of $57.35. The company has a market capitalization of $2.78 billion, a PE ratio of 946.49 and a beta of 1.66.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The company had revenue of $57.91 million for the quarter, compared to analysts' expectations of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%.

Institutional Investors Weigh In On Vericel

Hedge funds and other institutional investors have recently bought and sold shares of the business. International Assets Investment Management LLC increased its position in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 619 shares in the last quarter. CWM LLC lifted its position in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 504 shares in the last quarter. Farther Finance Advisors LLC lifted its position in Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new stake in Vericel during the 3rd quarter worth approximately $92,000.

Insider Buying and Selling at Vericel

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the business's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the sale, the director now directly owns 11,000 shares of the company's stock, valued at $454,960. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,166 shares of company stock valued at $1,200,764 over the last 90 days. 5.20% of the stock is owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.